Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Basic and Clinical Pharmacology and Toxicology(1)
Drug Safety(1)
Frontiers in Pharmacology(1)
Journal of Pharmaceutical Health Services Research(1)
PLoS ONE(1)
Área temáticas
Medicina y salud(5)
Problemas sociales y servicios a grupos(5)
Producción(2)
Salud y seguridad personal(1)
Origen
scopus(7)
A Novel Scale Linking Potency and Dosage to Estimate Anticholinergic Exposure in Older Adults: the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale
ArticleAbstract: Quantification of the anticholinergic exposure insufficiently or imprecisely incorporates dosage infPalabras claves:Autores:Azermai M., Carlos E. Durán, Christiaens T., Elseviers M., Klamer T., Vander Stichele R., Wauters M.Fuentes:scopusCorrection to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project (Drug Safety, (2022), 45, 4, (333-344), 10.1007/s40264-022-01154-7)
OtherAbstract: In the original version of this article, the given and family names of “Leonardo Roque Pereira” werePalabras claves:Autores:Carlos E. Durán, Kontogiorgis C., Lalagkas P.N., Layton D., Pereira L.R., Poulentzas G., Sturkenboom M.C.J.M.Fuentes:scopusEMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
OtherAbstract:Palabras claves:Autores:Cañás M., Carlos E. Durán, Chistiaens T.Fuentes:scopusMyocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries
ArticleAbstract: Background: Estimates of the association between COVID-19 vaccines and myo-/pericarditis risk vary wPalabras claves:adverse drug reaction, COVID-19 Vaccine, myocarditis , Pericarditis, pharmacovigilanceAutores:Alsina E., Aragón M., Belitser S.V., Bots S.H., Carlos E. Durán, Douglas I.J., García-Poza P., Gini R., Herings R.M.C., Huerta C., Klungel O.H., Martin I., Martín-Pérez M., Messina D., Overbeek J.A., Pallejà-Millán M., Paoletti O., Riera-Arnau J., Schultze A., Sisay M.M., Souverein P., Sturkenboom M.C.J.M., Swart K.M.A., Villalobos F.Fuentes:scopusSharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010–2014) consumption of oncologic drugs in public and private hospitals
ArticleAbstract: Objective: In Ecuador, a new constitutional mandate (2008) allowed the government to implement freePalabras claves:Cáncer, drug utilization, ECUADOR, health expenditures, Latin America, molecular targeted therapy, oncologic drugsAutores:Carlos E. Durán, Christiaens T., Elseviers M., Rottey S., Vander Stichele R.Fuentes:scopusRegulatory reliance to approve new medicinal products in Latin American and Caribbean countries
ArticleAbstract: Objective. To describe the current status of regulatory reliance in Latin America and the CaribbeanPalabras claves:Caribbean Region, Drug approval, Government Agencies, Latin America, Pan american health organization, Pharmaceutical preparations, United States Food and Drug AdministrationAutores:Andia T., Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.Fuentes:scopusPotential negative impact of reputed regulators decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis
ArticleAbstract: Background Many new cancer drugs are being approved by reputed regulatory authorities without evidenPalabras claves:Autores:Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.Fuentes:scopus